Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Brief Summary: The purpose of this study is to assess the clinical effectiveness and safety of golimumab intravenous (IV) infusions every 12 weeks with or without Methotrexate (MTX), compared with MTX alone, in patients with active rheumatoid arthritis (RA) despite concurrent MTX treatment. In addition, the safety of subcutaneous (SC) golimumab injections following transition from IV golimumab infusions will also be evaluated.


Options:
A: Arm Label: Certolizumab pegol 200 mg (CDP870); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg (CDP870) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group I: 2mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group II: 2mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group III: 4mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group IV: 4mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group V: IV Placebo + MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group II: 2mg/kg Golimumab only, Group III: 4mg/kg Golimumab + MTX, Group IV: 4mg/kg Golimumab only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group III: 4mg/kg Golimumab + MTX, Group V: IV Placebo + MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group II: 2mg/kg Golimumab only, Group IV: 4mg/kg Golimumab only, Group V: IV Placebo + MTX
C: Arm Label: Open-Label Active Treatment Enrolled from Phase 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Open-Label Active Treatment Enrolled from Phase 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 3
D: Arm Label: Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Arm Label: Infliximab + MTX (DB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab (INF) + MTX, DB | Arm Label: Placebo + MTX (DB); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (PLA) + MTX, DB | Arm Label: Placebo + MTX switched to abatacept + MTX (DB); Type: EXPERIMENTAL; Interventions: Drug: PLA + MTX switched to ABA+ MTX, DB | Arm Label: Abatacept (open-label); Type: EXPERIMENTAL; Interventions: Drug: ABA, open-label (OL) | Intervention Type: DRUG; Name: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB); Assigned to Arm(s): Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) | Intervention Type: DRUG; Name: Infliximab (INF) + MTX, DB; Assigned to Arm(s): Infliximab + MTX (DB) | Intervention Type: DRUG; Name: Placebo (PLA) + MTX, DB; Assigned to Arm(s): Placebo + MTX (DB) | Intervention Type: DRUG; Name: PLA + MTX switched to ABA+ MTX, DB; Assigned to Arm(s): Placebo + MTX switched to abatacept + MTX (DB) | Intervention Type: DRUG; Name: ABA, open-label (OL); Assigned to Arm(s): Abatacept (open-label)

Answer: B